Abstract：
Breast cancer is a heterogeneous disease, encompassing multiple different subtypes. Thanks to the increasing knowledge of the diverse biological features of each subtype, most patients receive personalized treatment based on known biomarkers. However, the role of some biomarkers in breast cancer evolution is still unknown, and their potential use as a therapeutic target is still underexplored. HER3 is a member of the human epidermal growth factors receptor family, overexpressed in 50%-70% of breast cancers. HER3 plays a key role in cancer progression, metastasis development, and drug resistance across all the breast cancer subtypes. Owing to its critical role in cancer progression, many HER3-targeting therapies have been developed over the past decade with conflicting findings. Next-generation antibody-drug conjugates have recently shown promising results in solid tumors expressing HER3, including breast cancer. In this review, we discuss the HER3 role in the pathogenesis of breast cancer and its relevance across all subtypes. We also explore the new anti-HER3 treatment strategies, calling into question the significance of HER3 detection as crucial information in breast cancer treatment.
摘要：
乳腺癌是一种异质性疾病，包含多个不同的亚型。由于对每个亚型的不同生物学特征的了解不断增加，大多数患者接受基于已知生物标志物的个性化治疗.然而,一些生物标志物在乳腺癌进化中的作用仍然未知，它们作为治疗靶点的潜在用途仍未得到充分开发。HER3是人类表皮生长因子受体家族的一员,在50％-70％的乳腺癌中过表达。HER3在癌症进展中起关键作用，转移发展，以及所有乳腺癌亚型的耐药性。由于其在癌症进展中的关键作用，在过去的10年中,许多HER3靶向疗法的研发结果相互矛盾.下一代抗体-药物缀合物最近在表达HER3的实体瘤(包括乳腺癌)中显示有希望的结果。在这次审查中,我们讨论了HER3在乳腺癌发病机制中的作用及其在所有亚型中的相关性.我们还探索了新的抗HER3治疗策略，质疑HER3检测作为乳腺癌治疗中重要信息的重要性。
